IP Library › Granted Patent US 12,226,484
Granted Patent B2
US 12,226,484 · App. 18/487,486 · Granted Feb 18, 2025

Compositions having improved bioavailability of therapeutics

Inventors: John Brew (St. Albans, GB); Daniel Gooding (Cambridge, GB); Robin M. Bannister (Saffron Walden, GB)
Assignee: TRx Biosciences Limited
A61K47/14A61K31/05A61K31/12A61K31/192A61K31/196A61K31/216A61K31/4025A61K31/4184A61K31/436A61K31/44A61K31/4418A61K31/4453A61K31/496A61K31/502A61K31/5377A61K31/553A61K31/58A61K31/7135A61K38/12A61K47/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,484
App. No.
18/487,486
Granted
Feb 18, 2025
Kind
B2
Abstract

The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C 14-24 fatty acids, one or more free C 14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.

Claims (28)

1. A pharmaceutical composition comprising:

a) one or more therapeutic compounds,

b) about 40% to about 80% by weight of the pharmaceutical composition of one or more glycerolipids, the one or more glycerolipids are one or more saturated C 10 -C 22 triglycerides and a mixture of unsaturated C 14 -C 22 monoglycerides, unsaturated C 14 -C 22 diglycerides, and unsaturated C 14 -C 22 triglycerides,

c) at least 5% to at most 50% by weight of the pharmaceutical composition of one or more free C 14 -C 22 fatty acids, and

d) about 0.5% to about 5.0% by weight of the pharmaceutical composition of one or more bile acids and/or one or more bile salts,

wherein the pharmaceutical composition is an anhydrous formulation, and

wherein the pharmaceutical composition is not an emulsion.

2. The pharmaceutical composition of claim 1 , wherein the one or more therapeutic compounds are in an amount of about 0.1% to about 25% by weight of the pharmaceutical composition.

3. The pharmaceutical composition of claim 1 , wherein the one or more therapeutic compounds are in an amount of about 25 mg/mL to about 600 mg/mL.

4. The pharmaceutical composition of claim 1 , wherein the one or more therapeutic compounds are in an amount of at most 250 mg/mL.

5. The pharmaceutical composition of claim 1 , wherein the one or more glycerolipids are in an amount of about 45% to about 65% by weight of the pharmaceutical composition.

6. The pharmaceutical composition of claim 1 , wherein the one or more glycerolipids are one or more saturated C 10 -C 22 triglycerides and a mixture of unsaturated C 16 -C 20 monoglycerides, C 16 -C 20 diglycerides, and C 16 -C 20 triglycerides.

7. The pharmaceutical composition of claim 1 , wherein the one or more saturated C 10 -C 22 triglycerides are present in an amount of about 10% to about 25% by weight of the pharmaceutical composition.

8. The pharmaceutical composition of claim 1 , wherein the one or more saturated C 10 -C 22 triglycerides and the mixture of unsaturated C 14 -C 22 monoglycerides, unsaturated C 14 -C 22 diglycerides, and unsaturated C 14 -C 22 triglycerides are in a triglyceride to mixture weight ratio of about 1:3 to about 1:1.

9. The pharmaceutical composition of claim 7 , wherein the one or more saturated C 10 -C 22 triglycerides are in an amount of about 15% to about 20% by weight of the pharmaceutical composition.

10. The pharmaceutical composition of claim 7 , wherein the one or more saturated C 10 -C 22 triglycerides are a mixture of saturated C 10 -C 18 triglycerides.

11. The pharmaceutical composition of claim 1 , wherein the free C 14-22 fatty acids are in an amount of about 20% to about 45% by weight of the pharmaceutical composition.

12. The pharmaceutical composition of claim 1 , wherein the free C 14-22 fatty acids are in an amount of 5% to about 20% by weight of the pharmaceutical composition.

13. The pharmaceutical composition of claim 1 , wherein the one or more free C 14-22 fatty acids comprise one or more free C 16-20 fatty acids.

14. The pharmaceutical composition of claim 1 , wherein the one or more free C 16-20 fatty acids is a stearic acid, an oleic acid, a linoleic acid, or any combination thereof.

15. The pharmaceutical composition of claim 1 , wherein the one or more bile acids and/or the one or more bile salts are in an amount of about 1.0% to about 3% by weight of the pharmaceutical composition.

16. The pharmaceutical composition of claim 1 , wherein the one or more bile acids is cholic acid, chenodeoxycholic acid, dafachronic acid, deoxycholic acid, glycocholic acid, glycohenodeoxycholic acid, lithocholic acid, taurochenodeoxycholic acid, taurocholic acid, any stereoisomer thereof, or any combination thereof.

17. The pharmaceutical composition of claim 1 , further comprising one or more free C 14-24 fatty acid surfactants, one or more phospholipids, or any combination thereof.

18. The pharmaceutical composition of claim 1 , wherein the one or more free C 14-22 fatty acids are one or more free C 16-20 fatty acids and one or more bile acids comprises cholic acid.

19. The pharmaceutical composition of claim 1 , wherein the one or more glycerolipids are a mixture of unsaturated C 16 -C 20 monoglycerides, C 16 -C 20 diglycerides, and C 16 -C 20 triglycerides, the one or more free C 14-22 fatty acids comprise one or more free C 16-20 fatty acids and one or more bile acids comprises cholic acid.

20. The pharmaceutical composition of claim 7 , wherein the one or more glycerolipids are one or more saturated C 10 -C 22 triglycerides and a mixture of unsaturated C 16 -C 20 monoglycerides, C 16 -C 20 diglycerides, and C 16 -C 20 triglycerides, the one or more free C 14-22 fatty acids are one or more free C 16-20 fatty acids, and one or more bile acids comprises cholic acid.

21. The pharmaceutical composition of claim 7 , wherein the one or more glycerolipids are a mixture of saturated C 10 -C 18 triglycerides and a mixture of unsaturated C 16 -C 20 monoglycerides, C 16 -C 20 diglycerides, and C 16 -C 20 triglycerides, the one or more free C 14-22 fatty acids are one or more free C 16-20 fatty acids, and one or more bile acids comprises cholic acid.

22. The pharmaceutical composition of claim 21 , wherein the mixture of saturated C 10 -C 18 triglycerides is in an amount of 10% to 30% by weight, the mixture of unsaturated C 16 -C 20 monoglycerides, C 16 -C 20 diglycerides, and C 16 -C 20 triglycerides is in an amount of 30% to 50% by weight, the one or more free C 16-20 fatty acids is in an amount of 30% to 50% by weight, and the cholic acid is in an amount of 1% to 5% by weight.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2024
From: BANNISTER, ROBIN M.; BREW, JOHN; GOODING, DANIEL
To: TRX BIOCIENCES LIMITED
Reel/Frame 066415/0594 →
Continuity (4)
Continuation 17656702 · Mar 28, 2022
Provisional Application 63269330 · Mar 14, 2022
Provisional Application 63166995 · Mar 27, 2021
Related Publication 20240075147A1 · Mar 7, 2024
References Cited (61)
US 5082667A · Scoik · 1992 [cited by applicant]
US 5885486A · Westesen et al. · 1999 [cited by applicant]
US 6063768A · First · 2000 [cited by applicant]
US 6294192B1 · Patel et al. · 2001 [cited by applicant]
US 6451339B2 · Patel et al. · 2002 [cited by applicant]
US 6569463B2 · Patel et al. · 2003 [cited by applicant]
US 6719999B2 · Liu et al. · 2004 [cited by applicant]
US 6720001B2 · Chen et al. · 2004 [cited by applicant]
US 6982281B1 · Chen et al. · 2006 [cited by applicant]
US 7374779B2 · Chen · 2008 [cited by examiner]
US 9339553B2 · Zhang et al. · 2016 [cited by applicant]
US 9861602B2 · Chen et al. · 2018 [cited by applicant]
US 20020028813A1 · Jackson et al. · 2002 [cited by applicant]
US 20060138059A1 · Vair, Jr. et al. · 2006 [cited by applicant]
US 20110195993A1 · Masson et al. · 2011 [cited by applicant]
US 20150150881A1 · Di Paolo et al. · 2015 [cited by applicant]
US 20180251422A1 · Martinez et al. · 2018 [cited by applicant]
US 20200368159A1 · Chen et al. · 2020 [cited by applicant]
US 20210346302A1 · Malhotra et al. · 2021 [cited by applicant]
CN 101366697A · 2009 [cited by examiner]
CN 101507707A · 2009 [cited by applicant]
CN 102813639A · 2012 [cited by applicant]
CN 113546045A · 2021 [cited by applicant]
EP 2220073B1 · 2014 [cited by applicant]
JP 2015508099A · 2015 [cited by applicant]
WO 2005053612A2 · 2005 [cited by applicant]
WO 2006017692A2 · 2006 [cited by applicant]
WO 2010041051A1 · 2010 [cited by applicant]
WO 2010075065A2 · 2010 [cited by applicant]
WO 2012104654A1 · 2012 [cited by applicant]
WO 2012104655A2 · 2012 [cited by applicant]
WO 2013126132A1 · 2013 [cited by applicant]
WO 2014108569A1 · 2014 [cited by applicant]
WO 2014108572A1 · 2014 [cited by applicant]
WO 2014108573A1 · 2014 [cited by applicant]
WO 2014108574A1 · 2014 [cited by applicant]
WO 2014117999A1 · 2014 [cited by applicant]
WO 2017025517A1 · 2017 [cited by applicant]
WO 2020217235A1 · 2020 [cited by applicant]
WO 2022207580A2 · 2022 [cited by applicant]
Voelker, D. R. “Glycerolipid structure, function, and synthesis in eukaryotes.” (2013): 412-418. (Year: 2013). [cited by examiner]
Shi, Feng, et al. “Formulation design, preparation, and in vitro and in vivo characterizations of β-elemene-loaded nanostructured lipid carriers.” International Journal of Nanomedicine (2013): 2533-2541. (Year: 2013). [cited by examiner]
Zhang, Cong, et al. “Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats.” International journal of nan… [cited by examiner]
Moghimipour, Eskandar, Abdulghani Ameri, and Somayeh Handali. “Absorption-enhancing effects of bile salts.” Molecules 20.8 (2015): 14451-14473. (Year: 2015). [cited by examiner]
Zhang, Xingwang, et al. “Pharmaceutical dispersion techniques for dissolution and bioavailability enhancement of poorly water-soluble drugs.” Pharmaceutics 10.3 (2018): 74. (Year: 2018). [cited by examiner]
Aboulfotouh, et al., Effect of Lipid Composition on RNA-Lipid Nanoparticle Properties and Their Sensitivity to Thin-Film Freezing and Drying, Int. J. Pharm. 650: 123688 (2024). [cited by applicant]
Esmaeli, et al., Preferential PPAR-α Activation Reduces Neuroinflammation, and Blocks Neurodegeneration in vivo, Hum. Mol. Genet. 25(2): 317-327 (2016). [cited by applicant]
Luo, et al., Impact of Formulation on the Quality and Stability of Freeze-Dried Nanoparticles, Eur. J. Pharm. Biopharm. 169: 256-267 (2021). [cited by applicant]
Metibemu, et al., Exploring receptor tyrosine kinases-inhibitors in Cancer treatments, Egypt. J. Med. Hum. Genet. 20(35): 1-16 (2019). [cited by applicant]
Pavlovic, et al., Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles, Front. Pharmacol. 9(1283): 1-23 (2018). [cited by applicant]
Sarjoj, et al., Current Trends in Lipid Based Delivery Systems and its Application in Drug Delivery, Asian J. Pharm. Clin. Res. 5(3): 4-9 (2012). [cited by applicant]
Schneid, et al., Optimization of the Secondary Drying Step in Freeze Drying Using TDLAS Technology, AAPS Pharm. Sci. Tech. 12(1):379-387 (2011). [cited by applicant]
Tsume, et al., The Biopharmaceutics Classification System: Subclasses for in vivo Predictive Dissolution (IPD) Methodology and IVIVC, Eur. J. Pharm. Sci. 57: 152-163 (2014). [cited by applicant]
Yousaf, et al., Enhanced Oral Bioavailability of Fenofibrate using Polymeric Nanoparticulated Systems: Physicochemical Characterization and in vivo Investigation, Int. J. Nanomed. 10: 1819-1830 (2015). [cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/EP2022/058180, pp. 5 (Nov. 17, 2022). [cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/EP2022/058180, pp. 11 (Nov. 17, 2022). [cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/EP2023/056491, pp. 5 (Jun. 15, 2023). [cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/EP2023/056491, pp. 8 (Jun. 15, 2023). [cited by applicant]
WIPO, PCT Form ISA210, International Search Report for International Patent Application Serial No. PCT/EP2023/056506, pp. 12 (Sep. 28, 2023). [cited by applicant]
WIPO, PCT Form ISA237, Written Opinion for International Patent Application Serial No. PCT/EP2023/056506, pp. 25 (Sep. 28, 2023). [cited by applicant]
WIPO, PCT Form IB373, International Preliminary Report on Patentability for International Patent Application Serial No. PCT/EP2022/058180, pp. 9 (Oct. 3, 2023). [cited by applicant]
Cited By (1)
US 12,533,332